For the minority of metastatic MM patients who exhibit BRAF V600E mutations, combined anti‐BRAF and anti‐MEK therapy may represent an adequate therapeutic strategy.17, 18. The gene discussed is MAP2K7; the disease is Miyoshi myopathy.